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Abstract
The tapeworm Echinococcus granulosus is responsible for cystic echinococcosis (CE), a
cosmopolitan disease which imposes a significant burden on the health and economy of
affected communities. Little is known about the molecular mechanisms whereby E. granulo-
sus is able to survive in the hostile mammalian host environment, avoiding attack by host
enzymes and evading immune responses, but protease inhibitors released by the parasite
are likely implicated. We identified two nucleotide sequences corresponding to secreted sin-
gle domain Kunitz type protease inhibitors (EgKIs) in the E. granulosus genome, and their
cDNAs were cloned, bacterially expressed and purified. EgKI-1 is highly expressed in the
oncosphere (egg) stage and is a potent chymotrypsin and neutrophil elastase inhibitor that
binds calcium and reduced neutrophil infiltration in a local inflammation model. EgKI-2 is
highly expressed in adult worms and is a potent inhibitor of trypsin. As powerful inhibitors of
mammalian intestinal proteases, the EgKIs may play a pivotal protective role in preventing
proteolytic enzyme attack thereby ensuring survival of E. granulosus within its mammalian
hosts. EgKI-1 may also be involved in the oncosphere in host immune evasion by inhibiting
neutrophil elastase and cathepsin G once this stage is exposed to the mammalian blood
system. In light of their key roles in protecting E. granulosus from host enzymatic attack, the
EgKI proteins represent potential intervention targets to control CE. This is important as
new public health measures against CE are required, given the inefficiencies of available
drugs and the current difficulties in its treatment and control. In addition, being a small sized
highly potent serine protease inhibitor, and an inhibitor of neutrophil chemotaxis, EgKI-1
may have clinical potential as a novel anti-inflammatory therapeutic.
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Author Summary
The hydatid tapeworm Echinococcus granulosus is able to survive in its mammalian hosts
for many years without being digested by proteases. Two E. granulosus Kunitz proteins
with potent protease inhibitory properties were identified and characterized. These Kunitz
proteins may provide protection to the parasite from proteolytic digestion. These newly
identified proteins are promising targets for developing new control interventions against
echinococcosis, and one has potential as a novel anti-inflammatory therapeutic.
Introduction
The dog tapeworm Echinococcus granulosus is one of a group of medically important parasitic
helminths of the family Taeniidae (Platyhelminthes; Cestoda; Cyclophyllidea). Its life cycle
involves two mammals: an intermediate host, usually a domestic or wild ungulate, with
humans being accidental hosts, and a canine definitive host such as the domestic dog. The lar-
val metacestode stage causes cystic echinococcosis (CE) (hydatidosis; cystic hydatid disease), a
chronic cyst-forming disease in the intermediate/human host [1]. Hermaphrodite adult worms
of E. granulosus reside in the small intestine of canines and pass eggs containing embryos
(oncospheres) in feces. Following ingestion by a human or an intermediate host such as a
sheep, the egg hatches in the intestine to release the oncosphere which penetrates through the
gut wall and is carried in the blood system to various internal organs, mainly the liver or lungs,
where it develops into a hydatid cyst. Dogs and other canines get infected by eating offal with
fertile hydatid cysts containing larval protoscoleces. These larvae evaginate, attach to the gut,
and develop into 3–6 mm long adult parasites which reach sexual maturity 4–5 weeks later [2].
The molecular mechanisms whereby the adult worms are able to survive in the dog gut without
being damaged from host intestinal proteases and how oncospheres evade host immune attack
in the blood system remain largely unknown. However, the recent deciphering of the E. granu-
losus genome and transcriptome [3, 4] provides insights as to how these processes might occur.
Kunitz type proteins, which belong to the I2 family of protease inhibitors, have been charac-
terized from many organisms including sea anemone [5], cone snail [6], scorpion [7], spider
[8], ticks and biting flies [9, 10], parasitic helminths [11–13] and mammals [14]. Bovine pan-
creatic trypsin inhibitor (BPTI) is the classic member of this family of proteins and was the
first Kunitz-type protease inhibitor described [15]. In invertebrates, Kunitz inhibitors are
involved in various physiological processes such as blood coagulation, fibrinolysis, inflamma-
tion and ion channel blocking with or without protease inhibition [16]. These proteins possess
one or more Kunitz domains; the Kunitz-type motif consists of around 60 amino acids and has
six conserved cysteine residues which connect with three disulphide bonds in a characteristic
pattern (C1-C6, C2-C4, and C3-C5). The C1-C6 and C3-C5 bonds are required for the mainte-
nance of native confirmation [17] whereas the C2-C4 bond stabilizes the folded structure [18].
Position P1 [19] of the reactive site is the major determinant of the energetic and specificity of
protease recognition by Kunitz inhibitors [20].
A previous study described a multigene family of eight (EgKU1-EgKU8) secreted monodo-
main Kunitz proteins from E. granulosus protoscoleces preferentially expressed by pepsin/H
(+)-treated worms [21]. Structural modeling revealed EgKU1 was a cation-channel blocker but
only EgKU8 behaved as a potential protease inhibitor suggesting the majority of these Kunitz
proteins were involved in functions other than protease inhibition [21].
By interrogation of the available genome sequence data for E. granulosus [3, 4] we identified
two gene sequences (designated EgKI-1 and EgKI-2) encoding two polypeptides similar to
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single domain Kunitz proteins. The two cDNAs were expressed in Escherichia coli, and the
recombinant proteins (rEgKI-1 and rEgKI-2) were purified and functionally characterized.
EgKI-2 reacted as a typical trypsin inhibitor, whereas EgKI-1, a potent inhibitor of chymotryp-
sin and neutrophil elastase, was able to significantly reduce neutrophil infiltration in the λ-car-
rageenan mouse air pouch model of local inflammation, and is the first Kunitz type serine
protease inhibitor shown to bind calcium.
Materials and Methods
Identification and expression of EgKI-1 and EgKI-2
Two nucleotide sequences (EgKI-1 and EgKI-2), encoding single domain Kunitz type protease
inhibitors, were identified by interrogation of available E. granulosus genomic sequence for
Kunitz domains. Searches for similar nucleotide sequences were performed using BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) on the NCBI (National Centre for Biotechnology
Information) web site. The presence of a signal sequence in both proteins was checked using
signalP 4.1 (http://www.cbs.dtu.dk/services/SignalP/) [22]. Protein domains were identified by
searching the PROSITE database (http://prosite.expasy.org/) [23] and multiple sequence align-
ment was generated with the Clustal Omega program (http://www.ebi.ac.uk/Tools/msa/
clustalo/) [24]. Protein structure prediction was performed with the Phyre2 online program
(www.sbg.bio.ic.ac.uk/phyre2/) [25] and binding site predictions were carried out with 3DLi-
gandSite (http://www.sbg.bio.ic.ac.uk/3dligandsite/) [26]. Other amino acid sequences of E.
granulosus, homologous to Kunitz proteins, were searched by blast using the GeneDB online
database (http://www.genedb.org/Homepage/Egranulosus). Cladogram phylogenetic analysis
was performed with Phylogeny.fr (http://www.phylogeny.fr/) [27].
PCR primers with introduced N-terminal 6×His tag and NcoI and EcoRI restriction sites,
(EgKI-1: FW- CATGCCATGGCACATCATCATCATCATCACGAAGAGGATGTCTGCAA
CCTACC, RV- GATCGAATTCCTATAAGTGCAAATTTTTAACACAAGCAC; EgKI-2:
FW- CATGCCATGGCACATCATCATCATCATCACCTTCACAGAGACTGCAAGGATCC,
RV- GATCGAATTCCTAGGCGATGGAGCATTGG) were designed and produced by Sigma
Aldrich (St. Louis, MO, USA). Both EgKI-1 and EgKI-2 were PCR-amplified using cDNA from
adult worms and MyTaq DNA polymerase. Purified PCR products were digested with the
restriction enzymes NcoI and EcoRI and ligated into the pET28a expression vector. Recombi-
nant protein production was induced after transforming the plasmids containing the EgKI
genes into E. coli BL21 (DE3) cells.
Recombinant protein production, refolding and purification were carried out as described
[11]. The concentrations of purified EgKI-1 and EgKI-2 were determined using the Bradford
assay and the proteins were stored at -80°C. Aliquots of the recombinant EgKI proteins were
subjected to electrophoresis on 15% (w/v) sodium dodecyl sulphate (SDS) polyacrylamide gels
and stained with Coomassie Blue to determine their purity and relative molecular mass.
Real time PCR
Preparations of cDNA from adult worms (AW), protoscoleces (PSC), hydatid cyst membranes
(HCM) and oncospheres (ONC) were used for real time PCR (qPCR); primers (EgKI-1: FW-
CGAAGAGGATGTCTGCAACC, RV- TCCACAACCACCGTAGATGA; EgKI-2: FW-
ACTGCAAGGATCCCATTGAC, RV- TCCTCCAGCGTCTCAAAGTT) were designed using
the online primer design software, Primer3 (http://simgene.com/Primer3). Each cDNA sample
(25 ng per reaction) was tested in quadruplicate and all reactions were performed twice. E.
granulosus eukaryotic translation initiation factor (Eg-eif) was used as housekeeping gene for
the normalization of data. The confidence threshold (CT) of the second results set was
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normalized to the first set before evaluation by importing the standard curve of the first set, to
the second. The results were analyzed using Rotor-Gene 6000 software.
Production of polyclonal antibodies against EgKI-1 and EgKI-2 proteins
Purified recombinant EgKI-1 and EgKI-2 were dialyzed in PBS using 3500 MWCO Slide-
A-Lyzer dialysis cassettes following the manufacturer’s instructions. Antiserum production
was undertaken using six Swiss mice per protein. For the first immunization each mouse was
inoculated subcutaneously with 50 μg of protein (dissolved in 50 μl PBS) emulsified with an
equal amount of Freund’s complete adjuvant. Subcutaneous boosts of 50 μg of protein (dis-
solved in 50 μl PBS), emulsified with the same amount of Freund’s incomplete adjuvant, were
undertaken on two occasions at two weekly intervals. Mice were bled for serum one week after
the third immunization and the presence of serum anti-EgKI antibodies was confirmed by
Western blotting. EgKI-1, EgKI-2, BPTI (Roche diagnostics, Mannheim, Germany), urinary
trypsin inhibitor (UTI) (Prospec-Tany TechnoGene Ltd, Ness Ziona, Israel) and SmKI protein,
0.5 μg each, were fractioned on a 15% (w/v) SDS-PAGE gel and transferred to Immun-Blot low
fluorescence-PVDF membrane. Overnight blocking was performed with Odyssey buffer at
4°C. Then, the membrane was subjected to incubation with the mouse anti-EgKI-1 or -EgKI-2
anti-serum (1:2,000 dilution in Odyssey buffer and 0.1% Tween-20) for 1 h followed by incuba-
tion with IRDye-labeled rabbit anti-mouse antibody (LI-COR Biosciences) (1:15,000 diluted in
Odyssey buffer with 0.1% Tween-20 and 0.01% SDS) for 1 h on a shaker in a dark chamber.
After a final wash with distilled water, the membrane was allowed to dry and visualized using
the Odyssey imaging system.
Western blotting and immunolocalization
Western blotting was carried out with both anti-EgKI-1 and anti-EgKI-2 antibodies using solu-
ble native extracts of AW, PSC, HCM and ONC as described [28]. Paraffin blocks were made
by embedding AW, HCM and PSC fixed in 10% phosphate buffered formalin in wax-filled
moulds. Sections (4 μm) of these paraffin blocks were then adhered onto microscope slides.
Following de-paraffinization and rehydration, antigen retrieval was done with RevealtA solu-
tion (Biocare Medical, Concord, CA, USA). Then the tissue sections were blocked with 1% (v/
v) bovine serum albumin in Tris buffered saline (TBS) for 1 h and incubated with the mouse
anti-EgKI-1 or -EgKI-2 anti-serum (1:200) at 4°C overnight. After washing with TBS-T (TBS
with 0.1% Tween20), the sections were incubated with Alexa Fluor 488 goat anti-mouse IgG
(1:500) (Invitrogen, Carlsbad, USA) at 37°C for 60 min. Nuclei in the tissue sections were
counterstained with DAPIgold (Invitrogen, Carlsbad, USA) and observed under an EVOS fluo-
rescence microscope.
Serine protease inhibition assays
The inhibitory activity of the two recombinant EgKI proteins was tested using several commer-
cially available mammalian serine proteases. Enzyme and EgKI protein mixture (ranging from
20 pM to 200 mM) were first incubated together in 96 well plates at 37°C for 10 min. Subse-
quently a chromogenic or fluorogenic substrate was added at concentrations ranging from 100
mM to 5 μM and product release was measured using a plate reader every min for 30 min.
Bovine pancreatic trypsin, bovine pancreatic α-chymotrypsin and the fluorogenic substrates
Nα-Benzoyl-L-arginine-7-amido-4-methylcoumarin hydrochloride and N-Succinyl-Ala-Ala-
Pro-Phe-7-amido-4-methylcoumarin were purchased from Sigma Aldrich (St Louis, USA).
Trypsin and chymotrypsin assays were performed in 200 mM Tris-HCl (pH 8.2) containing 20
mM CaCl2 and 0.1% PEG 8000. The kinetic rate of substrate hydrolysis was measured at
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excitation/emission wavelengths of 370/460 nm with a fluorescence microplate reader. Inhibi-
tory activity of porcine pancreatic elastase (PPE) was observed using the Enzcheck elastase
assay kit (Life technologies, Carlsbad, USA) following the manufacturer’s instructions. Fluores-
cence signals were measured at 505/515 nm.
Neutrophil elastase, Cathepsin G and Proteinase 3, with corresponding substrates N-Meth-
oxysuccinyl-Ala-Ala-Pro-Val-7-amino-4-methylcoumarin, Suc-Ala-Ala-Pro-Phe-pNA and
Boc-Ala-Ala-Nva-SBzl, respectively, were purchased from Enzolifesciences (NY, USA). The
neutrophil elastase (NE) inhibition assay was carried out with buffer containing 100 mM
HEPES, 300 mMNaCl and 0.05% Tween-20 (pH 8) with 2.5 nM enzyme and fluorescence sig-
nals were detected at 370/460 nm. Cathepsin G activity was determined in 100 mM Tris-HCl,
1.6 M NaCl buffer (pH 7.5) with 100 nM enzyme and release of Pro-Phe-pNA was measured at
405 nm. Buffer containing 100 mMHEPES pH 7.5, 500 mMNaCl, 10% DMSO was used to
detect Proteinase 3 activity and substrate hydrolysis was detected at 412 nm following the addi-
tion of 170 μM 5,5'-dithiobis (2-nitrobenzoic acid) (DTNB).
The percentage of the relative activity of the EgKI proteins was calculated using the formula:
Percentage of relative activity ¼ ðDRU of inhibitor= DRU of enzyme controlÞ  100%
Δ Relative ﬂuorescence/ absorbance unit (RU) = R2—R1, Readings R1 and R2 were taken at t1
and t2 time points respectively, when the reaction was in the linear range.
The data obtained with different substrate concentrations ([S]) and several inhibitor con-
centrations ([I], each EgKI protein) were fitted into the substrate-velocity curves of competitive
enzyme inhibition. Ki values were calculated using Graph Pad Prism version 6.02 software by
nonlinear regression according to the formula; v = Vmax [S]/ Km (1+ [I]/Ki) + [S], where v is
velocity, Vmax is the maximum velocity in the absence of inhibitor, and Km is the Michaelis
constant of the substrate. Values were corrected after subtracting background signals and all
experiments were performed in triplicates.
Coagulation assays
The clotting of blood involves multiple serine proteases so we performed two standard tests (acti-
vated partial thromboplastin time, APTT; and the prothrombin time, PT) to determine whether
the two recombinant EgKIs had any effect on the intrinsic and the extrinsic pathways of coagula-
tion. Fresh healthy human blood (30 ml) was collected into sodium citrate vacutainers and the
plasma was separated. Then, 800 μl plasma was mixed with 50 μl of each EgKI protein (final con-
centrations of 200 pM, 200 nM and 2 μM for EgKI-2 and 200 pM, 200 nM and 10 μM for EgKI-
1) and incubated in a 37°C water bath for 10 min. After adding CaCl2 to the mixture, the time
taken for clot formation was measured by a Sta-R coagulometer (Diagnostica stago, Asnières,
France). TriniCLOT APTT HS (Trinity Biotech, Bray, CoWicklow, Ireland) and Thromborel S
(Siemens, Malvern, PA, USA) kits were used for the determination of the APTT and the PT,
respectively. Aprotinin (Sigma Aldrich, St Louis, USA) and FVII negative plasma (Helena Labo-
ratories, Texas, USA) were used as positive controls for APTT and PT, respectively.
Calcium binding assay
As the 3DLigandsite predicted that EgKI-1 would bind calcium, a calcium binding assay was
carried out using a published procedure [29] with minor modifications to confirm the predic-
tion. Recombinant EgKI-1, recombinant EgKI-2 and bovine serum albumin (BSA) (New
England BioLabs), as positive control, were separated on 15% (w/v) SDS-PAGE gels and the
electrophoresed proteins transferred to a PVDF membrane. The membrane was washed with
wash buffer (10 mM imidazole, 60 mM potassium chloride, 5 mMmagnesium chloride, pH 6.8)
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for 1 h at 37°C with gentle shaking. After rinsing with distilled water, the blot was incubated
with 1 mM CaCl2 for 1 h. Following washing (3X) with 20% (v/v) ethanol and a final wash with
distilled water, the membrane was incubated with 1 mMQuin-2 (AM) (Sigma Aldrich) for 1 h.
Subsequently the membrane was washed with distilled water and visualized using a UV transil-
luminator (Vilber Lourmat) at 365 nm. Quin-2 emits fluorescence signals in the presence of
Ca++, enabling detection of proteins on the PVDF membrane bound to calcium.
Carrageenan mouse air pouch model of local inflammation
The subcutaneous air pouch model, which is an in vivomodel that can be used to study acute
and chronic inflammation, was used according to a published protocol [30]. Briefly, female
BALB/c mice weighing<25g were anesthetized with isoflurane and a subcutaneous dorsal
pouch was made in each animal by injecting 3 ml sterile air. The pouch was reinjected with 1.5
ml sterile air, after two days. On the sixth day, a 15 μM protein sample (rEgKI-1 or the anti-
inflammatory drug Ulinastatin [Prospec-Tany TechnoGene Ltd, Ness Ziona, Israel] as positive
control: 200 μl) in PBS or PBS alone as negative control was injected into the pouch. An LPS con-
trol (L2880; Sigma Aldrich) was also included and consisted of 12 μg of LPS, which was an
amount equivalent to the calculated LPS contamination of the bacterially produced rEgKI-1 pro-
tein measured using a Pierce LAL Chromogenic Endotoxin Quantitation Kit (Thermo Fisher
Scientific Inc., IL, USA) with a sensitivity of 0.1 EU/ml (approximately 0.01 ng endotoxin per
ml). After 30 mins, 300 μl of 1% (w/v) lambda (λ) carrageenan (Sigma Aldrich), which acts as an
inflammatory stimulus [31], in sterile saline, was injected into the air pouch. On the following
day, mice were euthanized and the pouches were washed with 1 ml ice cold lavage solution
(0.5% EDTA in 0.9% saline). The collected lavage solution was immediately placed on ice and
then centrifuged at 200 g for 10 min at 4°C. The resulting cell pellet was then resuspended in
500 μl lavage solution. Thin smears were made on microscope slides with the cell solution,
stained with Diffquick stain and examined under x100 magnification. Differential cell counts
were performed with the stained thin smears by counting 300 cells in total with the percentage of
neutrophils in each sample calculated. The total cell count in the lavage solution was determined
using a hemocytometer. Then, the total neutrophil count per mouse in the lavage solution was
calculated by multiplying the percentage of neutrophils by the total cell count. The experiment
was performed twice and in each case eight mice per group were used. Statistical analysis was
performed with one-way analysis of variance (ANOVA) using GraphPad prism 6. Statistical sig-
nificance was established at P< 0.05 compared with the PBS control and the LPS control.
Ethics statement
Human venous blood was prepared from a healthy volunteer after he/she provided informed
written consent and following review by the QIMRB Medical Research Institute (QIMRB)
Human Ethics Committee. All animal experimentation was conducted in strict accordance
with protocols approved by the QIMRB Animal Ethics Committee (project number P384),
which adheres to the Australian code of practice for the care and use of animals for scientific
purposes, as well as the Queensland Animal Care and Protection Act 2001; Queensland Animal
Care and Protection Regulation 2002.
Results
Identification and analysis of Kunitz protein genes
EG_08721 (GenBank: EUB56407.1), reported as being highly expressed in oncospheres and
EG_07242 (GenBank: EUB57880.1), reportedly highly expressed in adult worms [4] were
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selected for further characterization and named EgKI-1 and EgKI-2 respectively. The full-
length EgKI-1 and EgKI-2 cDNAs have open reading frames of 240 and 252 nucleotides. Both
translated peptides contain 18 amino acid signal sequences (Fig 1A) and have molecular
weights of 8.08 kDa (EgKI-1) and 8.3 kDa (EgKI-2). EgKI-1 has six conserved cysteine residues
whereas EgKI-2 has only five, apparently lacking the second disulphide bond (Fig 1B). A Clus-
tal alignment comparison of EgKI-1 and EgKI-2 with well characterized Kunitz inhibitors
available in GenBank revealed that the Kunitz family signature is highly conserved among dif-
ferent species (Fig 2A). Phylogenetic analysis of the two EgKIs (Fig 2B) confirmed their related-
ness with Kunitz protein sequences from other taxa. Further interrogation indicated the
presence of several other putative Kunitz inhibitors in the E. granulosus genome and transcrip-
tome [4], suggesting these proteins likely play an important role in the parasite’s biology. Some
of these Kunitz proteins contain a non inhibitory P1 amino acid whereas others contain a pro-
tease inhibitory amino acid. Also, several contain only Kunitz domains, whereas some associate
with other domains such as Ig or spondin. Clustal alignment performed with the ten putative
single domain Kunitz inhibitors of E. granulosus identified nine typical trypsin inhibitors and
one typical chymotrypsin inhibitor (S1 Fig).
Real time PCR
EgKI-1 was highly expressed in oncospheres, the infective stage of E. granulosus for humans
and intermediate hosts, such as sheep, whereas EgKI-2 was more highly expressed in adult
worms compared with EgKI-1 (Fig 3).
Protein expression, western blotting and immunolocalization
Purified yields of 1 mg/ L and 0.4 mg/ L, respectively, were obtained for recombinant EgKI-1
and EgKI-2 (Fig 4A). There was no cross immuno-reactivity between EgKI-1 and EgKI-2 as
shown by western blotting of the recombinant proteins with antisera from mice immunized
with the two proteins; moreover, neither antisera reacted with E. coli produced SmKI or to the
mammalian Kunitz proteins, BPTI and UTI (Fig 4B and 4C). There was no positive reactivity
with soluble antigen extracts from AW, PSC, HCM or ONC by either the anti-EgKI-1 or anti-
EgKI-2 murine antisera in western blots. A positive reaction was evident with the EgKI-2 anti
serum along the tegument of sections of adult worms (Fig 5) but no positive reactivity was
observed with sections from any of the life cycle stages probed with the EgKI-1 antiserum.
Calcium binding assay
According to the 3DLigandsite prediction, calcium ions bind with the glutamine (Glu) residue
at position 49 in EgKI-1 (Fig 6A). Recombinant EgKI-1 is shown to bind calcium more
strongly than EgKI-2 (Fig 6B).
Protease inhibition and coagulation assays
In serine protease inhibition assays (Table 1 and Fig 7) EgKI-2 reacted as a typical trypsin
inhibitor, having no significant inhibitory activity against the other tested proteases. EgKI-1
inhibited all tested proteases, except proteinase3, showing a high potency for inhibiting chymo-
trypsin and neutrophil elastase (Table 1 and Fig 7). Varying the pre-incubation time period of
the EgKI proteins with the serine proteases did not affect their inhibitory capacity suggesting
that they are not “slow binders” [32]. Moreover, the denatured EgKI-1 and EgKI-2 proteins in
4 and 8 M Urea showed no or only minor inhibitory activity indicating the necessity of correct
folding for inhibitory function (S2 Fig).
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Neither recombinant EgKI-1 nor EgKI-2 interfered with the blood coagulation pathway
when tested for APTT and PT. Neither protein prolonged the time taken for clot formation in
either test, indicating no or minimal inhibition of proteases involved in the coagulation cascade
(S3 Fig).
Mouse air pouch model
The results of the mouse air pouch model indicated that the infiltration of neutrophils to the
inflammatory site was significantly reduced by around 50% (P value<0.05) in the presence of
15 μM EgKI-1or the positive control Ulinastatin compared with the PBS control; injection of
the LPS control had no effect on the numbers of neutrophils infiltrating the pouch (Fig 8).
Discussion
The host-parasite relationship is complex being mediated both by parasite virulence factors
and exacerbated by host responses. The presence of Kunitz type proteins in numerous phyloge-
netically diverse species suggests that these molecules perform important biological functions
even though their precise role in each organism is not yet fully understood. We focused on two
nucleotide sequences (EgKI-1 and EgKI-2) encoding secreted single domain Kunitz type prote-
ase inhibitors (EgKI-1 and EgKI-2) from E. granulosus, that we had identified by interrogation
of the available genomic sequence. EgKI-1 has all six conserved cysteine residues present giving
rise to three disulphide bonds (C1-C6, C2-C4 and C3-C5) but EgKI-2 lacks the 2nd disulphide
bond (C2-C4). Previous studies have shown that the lack of the C2-C4 bond and even selective
Fig 1. Amino acid sequences of EgKI-1 (1) and EgKI-2 (2). A. Signal sequences (18 amino acids) are in red, the Kunitz domain of both proteins is boxed
and the Kunitz family signature highlighted in black. The conserved cysteine residues are shown in orange; EgKI-1 has six whereas EgKI-2 has five with one
position replaced by a glycine (blue). The P1 reactive sites of both proteins are highlighted in green. B. Schematic diagram of (i) EgKI-1 showing three
disulphide bridges, and (ii) EgKI-2 presenting two disulphide bridges.
doi:10.1371/journal.pntd.0004268.g001
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inhibition of the same bond has no effect on the stability of Kunitz proteins or their inhibitory
properties [33, 34]. Conkunitzin-S1 is a neurotoxin from the venom of the cone snail Conus
striatus which, despite missing the C2-C4 bond, retains its functional activity [35]. Further-
more, similar to EgKI-2, Huwentoxin-XI (HWTX-XI) from the venom of tarantula spiders
(Ornithoctonus sp), is a potent trypsin inhibitor despite lacking the 2nd disulphide bond [36].
Real time PCR showed EgKI-1 is highly expressed in the oncosphere which is the stage
infective to humans and ungulate hosts. The fact that EgKI-1 inhibited the activities of trypsin,
chymotrypsin and PPE may be a feature that helps protect oncospheres from digestion by
these enzymes in the small intestine of susceptible mammals. In contrast EgKI-2 is highly
expressed in adult worms and, as shown by immunofluorescence, the protein is localized to the
tegument, suggesting a possible role in protecting the parasite from the constant trypsin expo-
sure that it is subjected to in the small intestine of the canine definitive host. Due to the
Fig 2. A. Partial amino acid sequence comparison of EgKI-1 and EgKI-2 with other Kunitz type protease inhibitors from: Fasciola hepatica (FhKTM,
AAB46830.1); BPTI (1510193A); Echinococcus granulosus (EgKU8, ACM79010.1); Ancylostoma ceylanicum (AceKI, AAD51334.1);Conus striatus
(Conk-S1, P0C1X2.1); the first domain of Ancylostoma caninumKunitz inhibitor (Ac-KPI-1, AAN10061.1). The six conserved cysteine residues are
marked by * and the pattern of disulphide bond formation is shown in brackets. The P1 reactive site is marked by the arrow head and the Kunitz family
signature by the dashed double head arrow. B. Phylogenetic analysis of EgKI-1 and EgKI-2 with other Kunitz type protease inhibitors: FhKTM, EgKU8, BPTI,
SmKI, Conk-S1, human tissue factor pathway inhibitor-2 (TFPI-2, AAA20094), Black fly (Simulium vittatum) (Simukunin, ACH56928.1), Orb weaver spider
(Araneus ventricosus) (AvKTI, AFX95921.1), Black mamba (Dendroaspis polylepis) (DendrotoxinK, 1097974).
doi:10.1371/journal.pntd.0004268.g002
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considerable risk of handling and the difficulties in obtaining material, immunolocalization of
the two EgKIs in activated oncospheres was not possible. The fact that neither murine anti-
EgKI-1 nor anti-EgKI-2 antisera showed any positive reactivity with any of the western blot-
tested soluble antigen extracts from different life cycle stages of E. granulosus suggests that
either both EgKI proteins are produced in low quantity or are only expressed following an
external stimulus, such as when the worm comes in contact with host proteases. A recent tran-
scriptomic study identified five protease inhibitors, including EgKU8 [37], in the excretory/
secretory products of E. granulosus protoscoleces but more sensitive technologies may be
required to identify other proteins expressed at lower levels of abundance as may be the case
with EgKI-1 and EgKI-2.
The two Kunitz proteins were recombinantly expressed and purified by column refolding
from induced lysates of E. coli cells transformed with EgKI/pET28a plasmids. Refolding of bac-
terially produced protein inclusion bodies immobilized by nickel chelating chromatography is
a proven method for reconstituting the native properties of recombinant proteins and making
Fig 3. Normalized expression levels of the EgKI genes in E. granulosus. The Y axis represents the
number of copies after dividing the number of copies of either gene of interest (GOI) by the number of copies
of the house keeping gene (HKG). PSC, protoscoleces; AW, adult worms; HCM, hydatid cyst membrane;
ONC, oncospheres. Error bars represent the mean ± SEM.
doi:10.1371/journal.pntd.0004268.g003
Fig 4. (A) SDS-PAGE analysis andWestern blotting with mouse antisera raised against (B) EgKI-2 and (C) EgKI-1 proteins: Lane 1, EgKI-1; Lane 2,
EgKI-2; Lane 3, BPTI; Lane 4, UTI; Lane 5, SmKI; Lane M, protein marker. Aliquots of 3 μg from each protein sample were used for SDS-PAGE and
0.5 μg for western blotting.
doi:10.1371/journal.pntd.0004268.g004
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them suitable for structural and functional analysis [38]. As a result, we were able to show that
both EgKI proteins are potent serine protease inhibitors. Nanomolar range inhibition of tryp-
sin activity was disclosed for EgKI-2, while EgKI-1 inhibited chymotrypsin and neutrophil elas-
tase in the picomolar range. The specificity of a protease inhibitor against a protease is mainly
determined by the nature of the amino acid residue at position P1 of its active site. The results
we obtained with the EgKI proteins are in agreement with previous findings of Kunitz inhibi-
tors from other taxa, where typical trypsin inhibitors have Arg (R) or Lys (K) at P1, and chymo-
trypsin inhibitors have Leu (L) or Met (M) [39]; EgKI-1 and EgKI-2 have Leu and Arg residues
at the P1 site, respectively. The EgKIs are likely to play an important role in E. granulosus sur-
vival within their mammalian hosts and thus have potential as new drug and/or vaccine targets
as control interventions. EgKI-1 may prevent the oncosphere from being digested in the gut by
inhibiting trypsin, chymotrypsin and pancreatic elastase before it penetrates the intestinal wall.
Similarly, trypsin inhibition by EgKI-2 may help provide protection to the adult worms while
residing in the small intestine of the canine host.
Inflammatory responses occur after surgery, trauma and infection, and involve neutrophil
activation and infiltration into the injured tissue. Neutrophil infiltration also occurs in the
early stages of echinococcal infection [40]. Activated neutrophils release proteases such as neu-
trophil elastase, cathepsin G and proteinase 3 which, if not appropriately controlled, can result
in severe damage to healthy tissue. Uncontrolled proteolysis can lead to various diseases/
Fig 5. Immunolocalization of EgKI-2 in histological sections of an adult worm of E. granulosus (A) Bright field, (B) probed with pre-immune sera as
negative control, (C) probed with EgKI-2 immunized mouse serum (1:200).DAPI counterstained nuclei are stained blue and the positive green
fluorescence marks the presence of EgKI-2 along the tegument (t). Scale Bar = 100 μm.
doi:10.1371/journal.pntd.0004268.g005
Fig 6. (A) Predicted calcium binding site of EgKI-1, shown in blue. (B) Calcium binding assay:
SDS-PAGE gel (left) and corresponding western blot membrane of the calcium binding assay showing clear
bands corresponding to the EgKI-1 protein: M-Marker; 1, 6 μg EgKI-1; 2, 2 μg EgKI-1; 3, 6 μg EgKI-2; 4, 6 μg
BSA.
doi:10.1371/journal.pntd.0004268.g006
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disease syndromes including emphysema, idiopathic pulmonary fibrosis, respiratory distress
syndrome, cystic fibrosis, rheumatoid arthritis and glomerulonephritis [41]. Neutrophil elas-
tase is the major protease responsible for extracellular proteolysis and it plays a pivotal role in
the inflammatory response [42]. By releasing neutrophil elastase in the presence of foreign
material in blood, infiltrating neutrophils activate a signalling pathway which triggers macro-
phages to secrete cytokines as well as to attract more neutrophils [43].
The most potent, specific human neutrophil elastase inhibitor described to date is a protein
engineered from the Kunitz domain of human inter α inhibitor (EPI-HNE-4), which was
shown to have a Ki value of 5.45 x 10
−12 M [44]. Excessive accumulation of neutrophil elastase
in pulmonary fluids and tissues of patients with cystic fibrosis (CF) is thought to act on the
lungs, compromising their structure and function, so that EPI-HNE-4 has been suggested as an
anti-inflammatory compound for the treatment of CF [44]. We show here that EgKI-1 is also a
highly potent inhibitor (Ki = 6.42x10
-11 M) of neutrophil elastase and it thus warrants further
investigation as a potentially effective therapeutic for treating acute and chronic inflammatory
diseases.
Cathepsin G has chymotrypsin-like catalytic activity and also has potent pro-inflammatory
activity [42]. Calcium mobilization is one of the earliest events that occurs with neutrophil acti-
vation and is a key factor for modulating numerous neutrophil biological responses [45]. Once
stimulated, the intracellular Ca++ concentration within neutrophils rises rapidly due to mobili-
zation of ions from intracellular pools and influxes from the extracellular medium [46]. As well
as playing a role in preventing proteolytic damage to oncospheres by neutrophil elastase and
cathepsin G once they enter the blood circulation, EgKI-1, being a secretory protein, may also
act to suppress further neutrophil activation by binding calcium ions [45] in the extracellular
medium, thus making them unavailable to neutrophils.
Neutrophil chemotaxis plays an important role in the inflammatory response and, when
excessive or persistent, may augment tissue damage. The fact that neutrophils have a short life
span of around 6–8 hours after purification from whole blood is a limitation for performing
assays with primary neutrophils [47]. Resting neutrophils become primed and then mobilized
to the site of infection which involves receptor activation and secretion of cytokines, chemo-
kines and other components [41]. Because of this, the molecular properties of primed neutro-
phils are very different to their resting state. The regulatory functions of macrophages are also
shared by primed neutrophils. Hence, in vitro experiments with freshly isolated neutrophils
can often fail to recognize their full functional activity [41]. For a more complete understand-
ing of the functional activities of EgKI-1, we undertook in vivo experiments using the carra-
geenan induced mouse air pouch model. Subcutaneous injections of air over several days cause
morphological changes in the cellular lining of the pouch and resemble a synovial cavity [48].
As an irritant, λ-carrageenan induces localized inflammation characterized by the infiltration
of cells and a marked increase in the production of biochemical mediators. Thus, this model
Table 1. Inhibitor constant (Ki) values in Molar (M) range of EgKI-1 and EgKI-2.
Inhibitor Trypsin Chymotrypsin Pancreatic elastase Neutrophil elastase Cathepsin G
Ki (M) CI95 Ki (M) CI95 Ki (M) CI95 Ki (M) CI95 Ki (M) CI95
EgKI-1 2.32x10-7 0.17–0.28 1.484x10-9 0.20–0.62 1.65x10-9 1.23–2.06 6.42x10-11 32.74–95.66 4.47x10-10 0.20–0.62
EgKI-2 1.38x10-8 9.84–17.8 NI NI NI NI NI NI NI NI
NI- No inhibition,
CI95- 95% conﬁdence interval.
doi:10.1371/journal.pntd.0004268.t001
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Fig 7. Inhibition of different serine proteases with increasing concentrations of the EgKI proteins. The
relative activity (as a %) with: (A) nanomolar (nM) concentration range of EgKI-1 with trypsin, pancreatic
elastase and cathepsin G, and EgKI-2 with trypsin (B) picomolar (pM) concentration range of EgKI-1 with
neutrophil elastase and chymotrypsin. (C) Progress curves for trypsin inhibition with increasing
concentrations of EgKI-2 (0 nM, 10 nM, 20 nM, 100 nM) with different substrate concentrations ([S]).
doi:10.1371/journal.pntd.0004268.g007
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has been proven for use in pre-clinical studies of anti-inflammatory drugs [30]. It is notable
therefore that EgKI-1 significantly reduced neutrophil infiltration to the inflammatory site,
most likely as a result of its inhibition of neutrophil elastase. However, further studies are
needed for a more complete understanding of the activity of EgKI-1 against inflammatory
cytokines.
There is much current interest in developing novel potent drugs as treatments for inflam-
matory-related diseases to inhibit excessive and uncontrolled neutrophil serine protease activ-
ity [49, 50]. Clinical therapies that utilize protease inhibitors in controlling sepsis are currently
restricted to the use of urinary trypsin inhibitor (UTI), mainly in Japan [51]. UTI, also referred
to as ulinastatin or bikunin, is a multivalent Kunitz type serine protease inhibitor found in
human urine and produces several anti-inflammatory effects [52]. Proteases also play impor-
tant roles beyond their involvement in inflammation. In different types of cancers, the secre-
tion of various proteases correlates with the aggressiveness of the tumour. Kunitz type
inhibitors have been shown to exhibit promising anti-cancer properties which may be used in
their development as novel cancer therapies [53]. Bikunin [54], TFPI-2 [55] and SPINT2 [56]
are Kunitz proteins with anti-cancer effects, and as potent protease inhibitors, the EgKI pro-
teins may also exhibit similar properties which can be exploited in cancer therapy.
In summary, this study further broadens knowledge of E. granulosus biology and empha-
sises the potential importance of the EgKI Kunitz proteins in protecting the worm by inhibiting
or inactivating host digestive enzymes in the gut. As such they represent novel intervention tar-
gets for the control of cystic echinococcosis. Being a small molecule, a potent neutrophil elas-
tase inhibitor and an inhibitor of neutrophil chemotaxis, EgKI-1 warrants further study as a
potential therapeutic agent against inflammatory diseases [57]. As well, the potential anti-can-
cer effects of the EgKIs and their possible interactions with cytokines should be investigated.
Supporting Information
S1 Fig. Clustal alignment of the EgKI proteins with other single domain putative Kunitz
type protease inhibitors identified in the E. granulosus genome. The P1 reactive sites are
highlighted in black. Typical trypsin inhibitors have an arginine (R) at the P1 site whereas typi-
cal chymotrypsin inhibitors have a leucine (L).
(TIF)
Fig 8. Inhibition of neutrophil chemotaxis by EgKI-1 in the mouse air pouchmodel. The data represent
the mean ± SEM values of groups of eight mice in two independent experiments and analysis by one-way
ANOVA. * P value, 0.03; ** P value, 0.001; ns, not significant (p value 0.05).
doi:10.1371/journal.pntd.0004268.g008
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S2 Fig. Trypsin inhibition assays with denatured proteins (A) EgKI-1 (B) EgKI-2.
(TIF)
S3 Fig. APTT and PT with the EgKI proteins.
(TIF)
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